CrossBeta Biosciences Overview

  • Year Founded
  • 2005

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 3

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $10.4M

CrossBeta Biosciences General Information

Description

Developer of drug discovery and development platforms designed to generate stable oligomers. The company's platforms offer the discovery and development of multiple misfolded protein diseases, disease-specific antibodies, biomarker assays, and oral treatment of Alzheimer's disease, thereby enabling patients to avail quality drugs to recover from chronic diseases.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Parent Company
Corporate Office
  • PO Box 13283
  • 3507 LG Utrecht
  • Netherlands

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CrossBeta Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 30-Jan-2018 $10.4M 00.00 000.00 Completed Generating Revenue
5. Grant 18-Apr-2016 00000 00.00 Completed Generating Revenue
4. Later Stage VC 03-Mar-2013 00.00 Completed Generating Revenue
3. Grant 28-Aug-2011 00.000 00.00 Completed Generating Revenue
2. Early Stage VC 12-Apr-2010 $2.7M $2.7M Completed Startup
1. Spin-Off 01-Jan-2005 Completed Startup
To view CrossBeta Biosciences’s complete valuation and funding history, request access »

CrossBeta Biosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of drug discovery and development platforms designed to generate stable oligomers. The company's platforms off
Biotechnology
Utrecht, Netherlands
3 As of 2023
00.00
000.00 0000-00-00
000000&0 00.00

000000

isi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit i
0000 000000000
San Diego, CA
000 As of 0000
00000
00000000000 00000

000000

e irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat n
0000000000000
Gaithersburg, MD
00 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CrossBeta Biosciences Competitors (47)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cullgen Venture Capital-Backed San Diego, CA 000 00000 00000000000 00000
NexImmune Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
Arvinas Formerly VC-backed New Haven, CT 000 00000 000000000 00000
Kymera Therapeutics Formerly VC-backed Watertown, MA 000 00.000 00000000 00.000
Verge Genomics Venture Capital-Backed South San Francisco, CA 00 00000 0000000000 0 00000
You’re viewing 5 of 47 competitors. Get the full list »

CrossBeta Biosciences Patents

CrossBeta Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-2365825-A1 Cross-beta structures as carriers in vaccines Inactive 18-Nov-2008 0000000000
US-20110287047-A1 Cross-beta structures as carrier in vaccines Inactive 18-Nov-2008 0000000000 0
AU-2008325359-A1 Enhancement of immunogenicity of antigens Inactive 08-Nov-2007 0000000000
CA-2705242-A1 Enhancement of immunogenicity of antigens Inactive 08-Nov-2007 0000000000
US-20090142377-A1 Immunogenic compositions Inactive 08-Nov-2007 A61K39/145 00
To view CrossBeta Biosciences’s complete patent history, request access »

CrossBeta Biosciences Executive Team (5)

Name Title Board Seat Contact Info
Guus Scheefhals Chief Executive Officer
You’re viewing 1 of 5 executive team members. Get the full list »

CrossBeta Biosciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CrossBeta Biosciences Former Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
EuroTransBio Government 000 0000 000000 0
Michael J. Fox Foundation Limited Partner 000 0000 000000 0
Netherlands Enterprise Agency Government Minority 000 0000 000000 0
Rijksdienst voor Ondernemend Nederland Government 000 0000 000000 0
SenterNovem Corporation Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »

CrossBeta Biosciences FAQs

  • When was CrossBeta Biosciences founded?

    CrossBeta Biosciences was founded in 2005.

  • Who is the founder of CrossBeta Biosciences?

    Barend Bouma Ph.D is the founder of CrossBeta Biosciences.

  • Who is the CEO of CrossBeta Biosciences?

    Guus Scheefhals is the CEO of CrossBeta Biosciences.

  • Where is CrossBeta Biosciences headquartered?

    CrossBeta Biosciences is headquartered in Utrecht, Netherlands.

  • What is the size of CrossBeta Biosciences?

    CrossBeta Biosciences has 3 total employees.

  • What industry is CrossBeta Biosciences in?

    CrossBeta Biosciences’s primary industry is Biotechnology.

  • Is CrossBeta Biosciences a private or public company?

    CrossBeta Biosciences is a Private company.

  • What is the current valuation of CrossBeta Biosciences?

    The current valuation of CrossBeta Biosciences is 000.00.

  • What is CrossBeta Biosciences’s current revenue?

    The current revenue for CrossBeta Biosciences is 000000.

  • How much funding has CrossBeta Biosciences raised over time?

    CrossBeta Biosciences has raised $2.7M.

  • Who are CrossBeta Biosciences’s investors?

    EuroTransBio, Michael J. Fox Foundation, Netherlands Enterprise Agency, Rijksdienst voor Ondernemend Nederland, and SenterNovem are 5 of 6 investors who have invested in CrossBeta Biosciences.

  • Who are CrossBeta Biosciences’s competitors?

    Cullgen, NexImmune, Arvinas, Kymera Therapeutics, and Verge Genomics are some of the 47 competitors of CrossBeta Biosciences.

  • When was CrossBeta Biosciences acquired?

    CrossBeta Biosciences was acquired on 30-Jan-2018.

  • Who acquired CrossBeta Biosciences?

    CrossBeta Biosciences was acquired by ImmunoPrecise Antibodies.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »